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There is a growing interest in the role that fibrinogen
plays in major haemorrhage. It has been known since
1995 that fibrinogen is one of the first coagulation pro-
teins to fall to critically low levels during major blood
loss [1], but the clinical relevance of this is only now
being evaluated. Injury is the leading cause of death
worldwide for patients aged 1-45 and accounts for 7,800
deaths in UK annually. Uncontrolled haemorrhage is the
most common treatable cause of death in this popula-
tion; four out of every ten trauma patients die as a result
of exsanguination, or its late effects. Most trauma deaths
from haemorrhage occur within the first six hours of
hospital admission and early control of bleeding may
have a significant impact on mortality. By increasing
understanding of the precipitants of uncontrolled bleed-
ing (i.e. acute traumatic coagulopathy) and targeting
therapy accordingly, it is expected that major haemor-
rhage therapy and more importantly, clinical outcomes,
can be further improved. This short review briefly evalu-
ates what is known about fibrinogen during major
trauma haemorrhage, focusing on the changes that take
place during traumatic coagulopathy and the role that
fibrinogen supplementation may play in treatment of
trauma haemorrhage.
Transfusion therapy is an integral and costly part of
supportive treatment for major blood loss. A large UK
epidemiological study of patients with traumatic hae-
morrhage reported the annual cost to the NHS of treat-
ing major haemorrhage was £168 million (2012 prices)
(NIHR PGfAR: ‘Traumatic Coagulopathy & Massive
Transfusion: Improving Outcomes & Saving Blood,
2013). Early haemorrhage control may reduce this cost
but high quality evidence evaluating transfusion practice
for trauma haemorrhage is lacking. The results of a
recently completed North American study, PROPPR
(NCT01545232) which evaluated the effect of different
ratios of blood components (1:1:1 vs. 1:1:2 - FFP: plate-
lets:RBC) on mortality in 680 trauma patients are
eagerly awaited.
Thrombosis, as an appropriate response to bleeding, is
critically dependent on fibrinogen. Fibrinogen is cleaved
and activated by thrombin to produce insoluble fibrin
strands which form the basis of a stable clot. Fibrinogen
also acts as the ligand for platelet aggregation, thus loca-
lising platelets to a developing clot. FXIIIa then modifies
the fibrin matrix by binding to, and cross-linking, fibrin
strands and this leads to stabilisation and increased resis-
tance of the clot to fibrinolysis (FXIIIa covalently binds
alpha-2 anti-plasmin to fibrinogen). Fibrinogen levels fall
early during major haemorrhage reflecting many on-
going processes, including: factor consumption, dilution
(as a result of fluid therapy), fibrinolysis and fibrinogen-
olysis. Increased fibrinolysis has been shown to be a
major component of acute traumatic coagulopathy [2]
and is likely due to both the high levels of free tPA
released immediately after injury and the inhibition of
PAI-1 by activated protein C; resulting in increased plas-
min generation and clot degradation. Moreover, the
effects of fibrinolysis are likely exacerbated in trauma
haemorrhage by low fibrinogen levels, since fibrin strands
formed in a hypofibrinogenaemic environment are more
susceptible to lysis. These changes in fibrinolysis have
now been tested in a large trial of tranexamic acid [3].
Hypofibrinogenaemia has been shown to be an impor-
tant component of traumatic coagulopathy [4]. A recent
prospective analysis of 517 trauma patients demonstrated
that coagulopathic patients had significantly lower fibri-
nogen levels (1.6 g/L vs. 2.4 g/L; p < 0.001) upon arrival
in the emergency department compared to non-coagulo-
pathic patients [5]. Fibrinogen levels fell in association
with rising base deficit; falling systolic blood pressure and
high injury severity (ISS ≥ 25). The same group also
demonstrated that the presence of hypofibrinogenaemia
(i.e. < 1.5 g/L) at hospital admission was an independent
predictor of mortality, both at 24 hours and 28 days [5].
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Furthermore, for those patients with coagulopathy, ex
vivo addition of therapeutic concentrations of fibrinogen
(in the form of cryoprecipitate or fibrinogen concentrate
(FgC)), led to ‘reversal’ of acute traumatic coagulopathy
as defined by ROTEM measurements, providing early
evidence that fibrinogen supplementation may be of clin-
ical benefit in trauma haemorrhage.
There are clinical data to suggest that fibrinogen supple-
mentation may improve outcomes for trauma haemor-
rhage; by reducing blood loss and increasing survival.
Three observational studies have reported improved survi-
val with higher fibrinogen:RBC transfusion ratios in
trauma. In an uncontrolled observational trauma study of
131 haemorrhagic patients, mortality rates were reported
to fall by 14% after FgC treatment. Data outside trauma
also support the use of fibrinogen supplementation for
acquired bleeding. A small randomised placebo-controlled
cardiac study has confirmed that FgC can significantly
reduce (2 units vs. 13 units, p = < 0.001) total numbers of
allogeneic blood components transfused (RBC, FFP & pla-
telets), when administered using a ROTEM algorithm
(NCT00701142).
A recent systematic review appraising the management
of major bleeding in trauma and focusing on transfusion
therapy, found no high quality data supporting a safe and
effective fibrinogen level and found no completed trauma
RCTs evaluating the effect of FgC or cryoprecipitate [6].
Similarly, a Cochrane review evaluating FgC therapy high-
lighted inadequacies in the current published RCT litera-
ture; most studies were small and of poor methodological
quality [7].
The current standard source of fibrinogen in UK is cryo-
precipitate but fibrinogen concentrate (FgC) is increasingly
being used in Europe and there is a growing interest in its
use in UK. Cryoprecipitate (a pooled blood component
derived from whole blood donation) has a variable but
high fibrinogen concentration (15-20 g/L) and contains
additional coagulation factors (FVIII, FXIII, fibronectin,
von Willebrand factor), which may further contribute to
haemostasis. Cryoprecipitate requires thawing in a con-
trolled environment prior to transfusion, a process which
takes approximately 20 minutes. FgC (Riastap™) has been
used for many years for the treatment of inherited dys-/
hypo-fibrinogenaemia and has a good safety profile. It is
not licensed in UK for acquired bleeding disorders, such
as major haemorrhage. Riastap™ is a plasma product with
standardised fibrinogen content (20 g/L); is subjected to
viral inactivation (pasteurisation-heat treatment at +60°C
for 20 hours); and can be reconstituted at the bedside. The
cost per gram of fibrinogen in cryoprecipitate is £85 (2013
prices) compared to £400 for fibrinogen concentrate.
RCT evidence is urgently required to provide much
needed answers to questions, such as: does early fibrino-
gen supplementation improve clinical outcomes in
trauma haemorrhage; what dose of fibrinogen should be
administered; and which method of fibrinogen replace-
ment (FgC or cryoprecipitate) is more effective? A small
UK RCT (CRYOSTAT – ISRCTN55509212), evaluating
the feasibility of transfusing cryoprecipitate to trauma
patients within 90 minutes of randomisation, has
recently been completed. There is one other on-going
RCT (NCT01475344) in trauma which is evaluating the
effects of FgC on laboratory measures of fibrinogen
(FIBTEM), and may provide data which can guide fibri-
nogen dosing in major blood loss.
It is hoped that the preliminary data from pilot or feasi-
bility studies will support and inform the optimal design
of a larger RCT, evaluating the effects of cryoprecipitate or
FgC therapy on mortality and bleeding outcomes. But,
RCTs evaluating mortality endpoints require large num-
bers of participants and studies of this size require colla-
boration on a national or even international scale. This
will be an on-going challenge, but one that must be over-
come, if definitive trauma studies with relevant clinical
endpoints (e.g. mortality) are to be successfully completed.
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